OncoMatch/Clinical Trials/NCT07811752
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
Official title: The Efficacy and Safety of Sacituzumab Govitecan Plus Tislelizumab in Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Patients Who Progressed on Prior Immune Checkpoint Inhibitors (ICIs)
Is NCT07811752 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies Sacituzumab Tirumotecan (SKB264) plus Tislelizumab for esophageal squamous cell carcinoma.
Treatment: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab — This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell carcinoma whose disease has progressed following first-line immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immune checkpoint inhibitor plus chemotherapy — first-line
Cannot have received: trop2-targeted therapy
Cannot have received: topoisomerase i inhibitor
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L; platelet count ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L
Kidney function
creatinine clearance ≥ 50 mL/min, calculated using the Cockcroft-Gault formula
Liver function
AST and ALT ≤ 2.5 × ULN; for subjects with baseline liver metastases, AST and ALT ≤ 5 × ULN; serum albumin ≥ 30 g/L; total bilirubin ≤ 1.5 × ULN
adequate organ and bone marrow function, without receiving blood transfusion, recombinant human thrombopoietin, or colony-stimulating factor treatment within 2 weeks prior to the first dose, as defined by all of the following laboratory criteria: ... (see full text for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07811752 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior trop2-targeted therapy, topoisomerase i inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages